| DB ID | MyCo_3159 |
| Title | Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients |
| Year | 2021 |
| PMID | 34495710 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | COVID-19 |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Multi-Location |
| Cohort | Between 8 February 2020 and 22 May 2020, 219 critically ill COVID-19 patients admitted to the ICU were included from the rst COVID-19 wave. |
| Cohort No. | 219 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad, Marnes la Coquette, France) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay, FDA Approved -Platelia Aspergillus ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
